Document is current

Article History

Received: 24 March 2025

Accepted: 20 June 2025

First Online: 11 August 2025

Declarations

:

: P.J.F. reports no conflicts of interest. I.G.E. has received speakers’ bureau expenses from Leo-pharma, Rovi, Amgen, and Merck. C.G. has received research funding. J.A.G. has received funding for travel and accommodation from MSD, Amgen, Merck, and Servier and speakers’ bureau expenses from Merck, Servier, Amgen, and Sanofi. A.F.M. has received honoraria from Servier, MSD, Roche, BMS, Pierre Fabre, AstraZeneca; speakers’ bureau expenses from MSD, Astellas, and Merck; and travel funding from Roche and AstraZeneca. E.A.A. has received research funding from Roche and consulting expenses from Amgen, Bayer, Bristol Myers Squibb, Merck, Roche, Sanofi, and Servier. I.M.G. has received consulting expenses from Daychi; speakers’ bureau expenses from Gilead; and travel funding from Taiho. C.M.V. has received consulting expenses from Roche, Merck, and Takeda and speakers ‘ bureau expenses from MSD, Pfizer, and Amgen. E.E. has received funding from Abbvie Deutschland GmbH & Co KG, Agenus, Amgen Inc., Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharma AG, Bayer, BeiGene, Bioncotech Therapeutics, S.L., Biontech RNA Pharmaceuticals GMBH, Biontech Small Molecules GMBH, Boehringer Ingelheim, Boehringer Ingelheim de España S.A., Bristol Myers Squibb International Corporation (BMS), Celgene International SARL, Cure Teq AG, Daiichi Sankyo, Inc, Debiopharm International SA, Enterome BioScience SA, Exelixis, Genentech Inc, Gercor, GlaxoSmithKline (GSK), HalioDX SAS, Hoffmann-La Roche Ltd, Hutchison Medipharma Limited, Hutchison MediPharma International, Iovance Biotherapeutics, Inc., Janssen Research & Development, Janssen-Cilag SA, Janssen, Lilly, MedImmune, Medscape, Menarini, Menarini Ricerche SPA, Merck Health KGAA, Merck Serono, Merck, Sharp & Dohme de España S.A. (MSD), Merus NV, Mirati, Nouscom SRL, Novartis Farmacéutica SA, Novartis, NuCana plc., Organon, PharmaMar SA, Pfizer, Pierre Fabre, Pledpharma AB, Redx Pharma PLC, Repare Therapeutics Inc., RIN Institute Inc., Sanofi Aventis Recherche & Développement, Sanofi, Scandion Oncology, Seattle Genetics Inc. (Seagen International GmbH), Servier, Sotio A.S., Taiho Pharma USA Inc, Takeda, and Wntresearch AB. C.S.V. has received speakers’ bureau expenses from AMGEN and travel funding from Amgen and Merck.

: This study does not involve human participants or animals, and therefore formal ethical approval and informed consent are not required.